ChromaDex (CDXC)
(Delayed Data from NSDQ)
$3.38 USD
-0.09 (-2.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.38 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth A Momentum B VGM
Company Summary
ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico.
Company Summary
General Information
ChromaDex Corporation
10900 Wilshire Blvd. Suite 600
Los Angeles, CA 90024
Phone: 310-388-6706
Fax: 949-419-0294
Email: investorrelations@chromadex.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.01 |
Current Year EPS Consensus Estimate | 0.01 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 3.47 |
52 Week High | 4.65 |
52 Week Low | 1.25 |
Beta | 1.86 |
20 Day Moving Average | 277,105.00 |
Target Price Consensus | 6.23 |
4 Week | 6.44 |
12 Week | 20.49 |
YTD | 142.66 |
4 Week | 2.77 |
12 Week | 18.05 |
YTD | 103.06 |
Shares Outstanding (millions) | 75.93 |
Market Capitalization (millions) | 263.49 |
Short Ratio | NA |
Last Split Date | 4/13/2016 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 347.00 |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 100.00% |
vs. Previous Quarter | 100.00% |
vs. Previous Year | 11.89% |
vs. Previous Quarter | 2.65% |
Price/Book | 8.53 |
Price/Cash Flow | NA |
Price / Sales | 3.08 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -4.68 |
3/31/24 | -12.61 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -2.50 |
3/31/24 | -6.54 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.76 |
3/31/24 | 2.52 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.12 |
3/31/24 | 1.88 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -1.58 |
3/31/24 | -4.24 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -1.58 |
3/31/24 | -4.24 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -1.58 |
3/31/24 | -4.24 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.41 |
3/31/24 | 0.38 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 2.62 |
3/31/24 | 2.51 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.02 |
3/31/24 | 0.03 |